20:00 , Apr 26, 2019 |  BC Week In Review  |  Clinical News

Prothena sees potential path forward for amyloidosis candidate

Prothena said it will explore business development opportunities that could lead to further clinical investigation of amyloid light-chain (AL) amyloidosis candidate birtamimab (NEOD001) after post hoc analyses of the Phase III VITAL trial showed a...
20:04 , Feb 4, 2019 |  BC Extra  |  Company News

Management tracks: PhRMA, Amgen, Apellis

Sanofi (NASDAQ:SNY; Euronext:SAN) CEO Olivier Brandicourt became chairman of PhRMA. Brandicourt was chairman-elect and succeeds Robert Bradway, who is chairman and CEO of Amgen Inc. (NASDAQ:AMGN). PhRMA named Giovanni Caforio chairman-elect. Caforio is chairman and...
23:01 , Jan 31, 2019 |  BC Extra  |  Company News

Management tracks: Calico, Apellis, Immutep

Calico Life Sciences LLC (South San Francisco, Calif.) hired Aarif Khakoo as its first head of drug development. He will lead the company’s early stage development from candidate selection through Phase II. Khakoo was VP...
19:20 , Jan 31, 2019 |  BC Extra  |  Company News

Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis....
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
18:45 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
22:27 , Nov 2, 2018 |  BC Extra  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
20:52 , Jul 31, 2018 |  BC Extra  |  Company News

Management tracks: Canbridge, Retrophin

Canbridge Life Sciences Ltd. (Beijing, China) hired May Orfali as CMO. She succeeds interim CMO Mark Goldberg. Orfali was executive director of global product development at Pfizer Inc. (NYSE:PFE). Rare disease company Retrophin Inc. (NASDAQ:RTRX)...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
00:06 , Jun 28, 2018 |  BC Extra  |  Company News

Management tracks: Arrakis, Astellas

Arrakis Therapeutics Inc. (Waltham, Mass.) founder and CSO Russ Petter is transitioning to Jennifer Petter. The news was announced in a blog post by Chairman and CEO Michael Gilman. "The support for this transition at...